JP2005506524A - 血管新生の阻害剤をスクリーニングおよび使用する方法 - Google Patents

血管新生の阻害剤をスクリーニングおよび使用する方法 Download PDF

Info

Publication number
JP2005506524A
JP2005506524A JP2002579991A JP2002579991A JP2005506524A JP 2005506524 A JP2005506524 A JP 2005506524A JP 2002579991 A JP2002579991 A JP 2002579991A JP 2002579991 A JP2002579991 A JP 2002579991A JP 2005506524 A JP2005506524 A JP 2005506524A
Authority
JP
Japan
Prior art keywords
mmp
subunit
integrin
angiogenesis
mti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002579991A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506524A5 (enExample
Inventor
ピーター・シー・バシュウ
ヘイイン・ジャン
バーナ・エム・マニュエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2005506524A publication Critical patent/JP2005506524A/ja
Publication of JP2005506524A5 publication Critical patent/JP2005506524A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2002579991A 2001-04-04 2002-04-03 血管新生の阻害剤をスクリーニングおよび使用する方法 Withdrawn JP2005506524A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28151201P 2001-04-04 2001-04-04
PCT/US2002/010501 WO2002081627A2 (en) 2001-04-04 2002-04-03 Methods of screening and using inhibitors of angiogenesis

Publications (2)

Publication Number Publication Date
JP2005506524A true JP2005506524A (ja) 2005-03-03
JP2005506524A5 JP2005506524A5 (enExample) 2006-01-05

Family

ID=23077607

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002579991A Withdrawn JP2005506524A (ja) 2001-04-04 2002-04-03 血管新生の阻害剤をスクリーニングおよび使用する方法

Country Status (5)

Country Link
US (2) US20030171271A1 (enExample)
EP (1) EP1393075A4 (enExample)
JP (1) JP2005506524A (enExample)
CA (1) CA2443378A1 (enExample)
WO (1) WO2002081627A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8574827B2 (en) 2002-10-29 2013-11-05 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis and tumorigenesis
WO2005080984A1 (en) * 2004-02-17 2005-09-01 Rigel Pharmaceuticals, Incorporated Modulators of angiogenesis and tumorigenesis
HRP20130782T1 (en) * 2004-04-02 2013-09-30 The Regents Of The University Of California, Office Of Technology Transfer Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
NO323175B1 (no) 2004-12-23 2007-01-15 Jan O Aasly Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme
EP2456460A4 (en) 2009-07-24 2013-02-20 Univ California METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASES ASSOCIATED WITH AVB5 INTEGRIN

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022948A (en) * 1996-09-17 2000-02-08 Washington University Method of cell surface activation and inhibition

Also Published As

Publication number Publication date
EP1393075A4 (en) 2006-06-14
CA2443378A1 (en) 2002-10-17
US20030171271A1 (en) 2003-09-11
US20040126825A1 (en) 2004-07-01
EP1393075A2 (en) 2004-03-03
WO2002081627A2 (en) 2002-10-17
WO2002081627A3 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
Azar Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis)
Zhang et al. Expression of integrins and MMPs during alkaline-burn-induced corneal angiogenesis
Liotta Tumor invasion and metastases: role of the basement membrane. Warner-Lambert Parke-Davis Award lecture
Fini et al. Proteolytic mechanisms in corneal ulceration and repair
Andreasen et al. The urokinase‐type plasminogen activator system in cancer metastasis: a review
Mousa Mechanisms of angiogenesis in vascular disorders: potential therapeutic targets
Kvanta et al. Matrix metalloproteinase (MMP) expression in experimental choroidal neovascularization
Vince et al. Heterogeneous regional expression patterns of matrix metalloproteinases in human malignant gliomas
JP2005506524A (ja) 血管新生の阻害剤をスクリーニングおよび使用する方法
US20050129681A1 (en) Methods for inhibiting angiogenesis
Rolfsen et al. Corneal neovascularization: a review of the molecular biology and current therapies
Ohlmann et al. Localization of collagen XVIII and endostatin in the human eye
US8389476B2 (en) Parstatin peptides and uses thereof
Nishiura et al. Expression of matrix metalloproteinase-3 in mouse endometrial stromal cells during early pregnancy: Regulation by interleukin-1α and tenascin-C
Nagavarapu et al. Membrane type 1 matrix metalloproteinase regulates cellular invasiveness and survival in cutaneous epidermal cells
Sivak et al. Pharmacologic uncoupling of angiogenesis and inflammation during initiation of pathological corneal neovascularization
WO2005092381A1 (en) Use of emmprin antagonists for the treatment of diseases associated with excessive angiogenesis
AU2002307096A1 (en) Methods of screening and using inhibitors of angiogenesis
Vince et al. Medulloblastoma displays distinct regional matrix metalloprotease expression
Goodman et al. Unique parameters in the healing of linear partial thickness penetrating corneal incisions in rabbit: immunohistochemical evaluation
US20050214302A1 (en) Use of emmprin antagonists for the treatment of diseases associated with excessive angiogenesis
Johnson The Role of Plasminogen Activator Inhibitor Type 2 (PAI-2) in Venous Thrombus Resolution
Yeow Functional analysis of sorsby's fundus dystrophy mutant TIMP-3
Maret Mechanism of tumor cell invasion and metastasis based on loss of adhesion: the role of altered N-cadherin processing
JP2004522702A (ja) 血管形成の調節

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050310

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20061020